Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
William Murphy
University of Wisconsin Madison, Department: Physical Medicine & Rehab
Should you be removed from our database? Contact us at [email protected]. Read more below.
Stem Pharm, Inc.
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
An outside activity has a nexus with an individual's research activities if the outside activity arises from, relies upon or is related to the academic expertise that qualifies that individual to participate in federally funded research or human subjects research. The Institution has reasonably determined that the significant financial interest could directly and significantly affect the design, conduct, or reporting of the PHS-funded research and so requires management.
Matrices for optimal endogenous progenitor cell recruitment and function
Insufficient neovascularization is often the cause of poor clinical outcome during wound healing, and remains one of the foremost challenges in tissue engineering and regenerative medicine. Many strategies have been designed to induce neovascularization in healing tissues, including delivery of pro-angiogenic proteins and pro- angiogenic cells. However, clinical strategies have not yet achieved a high level of efficacy for treatment of ischemic conditions. A compelling approach to this problem involves delivery of circulating angiogenic cells (CACs), which can secrete multiple pro-angiogenic cues that induce neovascularization at sites of tissue damage. Recent CAC delivery strategies have demonstrated some efficacy for treatment of coronary artery disease, myocardial ischemia, and myocardial infarction, and CAC delivery is also being used to treat diabetic wounds and large bone defects. Taken together, these studies suggest that CAC delivery is a promising clinical approach. However, clinical applications of CACs are limited by low prevalence in blood and challenging regulatory approval for strategies that involve ex vivo cell manipulation. We propose an approach to discover materials that optimally recruit functional CACs already present in the human bloodstream. Our proposed approach to leverage endogenous CACs could have a substantial impact on treatments of diseases (e.g. diabetes, coronary artery disease), as well as emerging tissue regeneration schemes.
Filed on February 25, 2016.
Tell us what you know about William Murphy's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
William Murphy filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| William Murphy | University of Wisconsin Madison | Conflict of Interest | Tissue Regeneration Systems, Inc. | $60,000 - $79,999 |
| William Murphy | University of Wisconsin Madison | Conflict of Interest | Tissue Regeneration Systems, Inc. | $20,000 - $39,999 |
| William Murphy | University of Wisconsin Madison | Conflict of Interest | Tissue Regeneration Systems, Inc. | $20,000 - $39,999 |
| William Murphy | University of Wisconsin Madison | Conflict of Interest | Stem Pharm, Inc. | $5,000 - $9,999 |
| William Murphy | University of Wisconsin Madison | Conflict of Interest | Morgridge Institute for Research | $5,000 - $9,999 |
| William Murphy | University of Wisconsin Madison | Conflict of Interest | Tissue Regeneration Systems, Inc. | Value cannot be readily determined |
| William Murphy | University of Wisconsin Madison | Conflict of Interest | Tissue Regeneration Systems, Inc. | Value cannot be readily determined |
| William Murphy | University of Wisconsin Madison | Conflict of Interest | Stem Pharm, Inc. | Value cannot be readily determined |
| William Murphy | University of Wisconsin Madison | Conflict of Interest | Stem Pharm, Inc. | Value cannot be readily determined |
| William Murphy | University of Wisconsin Madison | Conflict of Interest | Tissue Regeneration Systems, Inc. | Value cannot be readily determined |
| William Murphy | University of Wisconsin Madison | Conflict of Interest | Dianomi Therapeutics | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.